Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Bexagliflozin with Exenatide in Healthy Subjects
NCT03167411Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- May 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Theracos, Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time of Maximum Observed Plasma Concentration and 2 more. Started May 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03167411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167411.